Diane C. Young - 17 Aug 2022 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
SVP, CHIEF MEDICAL OFFICER
Signature
/s/ Sam Martin, attorney-in-fact for Diane C. Young
Issuer symbol
CLDX
Transactions as of
17 Aug 2022
Net transactions value
-$389,545
Form type
4
Filing time
19 Aug 2022, 16:05:55 UTC
Previous filing
17 Jun 2022
Next filing
20 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDX Common Stock Options Exercise $197,220 +19,000 +898% $10.38 21,115 17 Aug 2022 Direct
transaction CLDX Common Stock Sale $708,715 -19,000 -90% $37.30 2,115 17 Aug 2022 Direct F1
transaction CLDX Common Stock Options Exercise $121,950 +45,000 +2128% $2.71* 47,115 17 Aug 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Incentive Stock Option Options Exercise $0 -19,000 -28% $0.000000 48,400 17 Aug 2022 Common Stock 19,000 $10.38 Direct F2
transaction CLDX Incentive Stock Option Options Exercise $0 -45,000 -75% $0.000000 15,000 17 Aug 2022 Common Stock 45,000 $2.71 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.30 to $37.35 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F2 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
F3 25% vested on July 8, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.